Walmart joins Arkansas initiative to transform care delivery

Luke Gale | | Health Exec | Policy & Regulations

Walmart has committed $670,000 to underwrite the Arkansas Payment Improvement Initiative, a statewide effort to transform healthcare delivery with the hopes of containing costs and improving quality.

By encouraging providers to engage in a variety of potentially cost-effective strategies, including patient engagement, care coordination and increased provision of preventive services, the Arkansas Payment Improvement Initiative is intended to increase the value of healthcare provided throughout the state, according to a statement. In addition to funding the public communications program and underwriting an annual statewide tracking report, Walmart also will serve on the initiative’s employer advisory council. 

Luke Gale

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.